What are the reported procedural costs of vascular access surgery?

Autor:	Edgar B; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK.; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Jones C; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK.; School of Health and Wellbeing, University of Glasgow, Glasgow, UK., Aitken E; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK.; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Stevenson K; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK., Jackson A; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK., Gaianu L; Independent Health Economist, Healthonomics UK Ltd, Reading, UK., Thomson P; Department of Renal Medicine, Queen Elizabeth University Hospital, Glasgow, UK., Kasthuri R; Department of Interventional Radiology, Queen Elizabeth University Hospital, Glasgow, UK., Stove C; Department of Interventional Radiology, Queen Elizabeth University Hospital, Glasgow, UK., Kingsmore DB; Renal Transplant and Vascular Access Surgery, Queen Elizabeth University Hospital, Glasgow, UK.; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.; Department of Vascular Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
Jazyk:	angličtina
Zdroj:	The journal of vascular access [J Vasc Access] 2024 Sep 30, pp. 11297298241284737. Date of Electronic Publication: 2024 Sep 30.
DOI:	10.1177/11297298241284737
Abstrakt:	Introduction: Since the inception of arteriovenous grafts (AVG) as a novel technique, there has been greater emphasis on the assessment of outcomes rather than costs. Gross-costing methods over-simplify vascular access surgery and do not reflect the true costs of the service, preventing accurate cost-effectiveness analysis. The aim of this study is to assess the reporting of procedural costs of arteriovenous access creation in economic analyses of vascular access surgery, and to compare the reported costs of the two most performed procedures - arteriovenous fistula (AVF) and arteriovenous graft (AVG). Methods: This systematic review included studies reporting a per-procedure cost for AVF or AVG creation. Costs were adjusted from original to target price year using a Gross Domestic Product (GDP) deflator index and converted to 2021 US Dollars using conversion rates based on purchasing power parities. Results: The results demonstrate wide discrepancy in the reported procedural costs of arteriovenous access creation. Most of the data represents retrospectively observed costs rather than prospective data collected on an intention-to-treat basis. Charges are frequently presented in lieu of costs, and aggregated gross-costing methodology predominates rather than more accurate micro-costing. Conclusion: Future micro-costing studies of vascular access surgery are essential to allow a greater understanding of cost-drivers and allow accurate cost-effectiveness analysis. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu